RxDoctor Payments Data

Elizabeth Kidder, MD

Internal Medicine · Jamestown, NYNPI 1407276587

Payments from drug & device makers

$4,618in general payments, 2019–2025

Across 232 payments — averaging $19.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$798
  • GSK$574
  • Novo Nordisk$454
  • AbbVie$417
  • Novartis$234
  • Amgen$233
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$4,46099%
  • Education$80%
  • Other$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,618 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$1,618
Medicare patients
56
Services billed
120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide92$103,818
JardianceEmpagliflozin83$76,672
EliquisApixaban84$76,259
MounjaroTirzepatide56$68,999
Breo ElliptaFluticasone/Vilanterol62$31,644
JanuviaSitagliptin Phosphate30$28,911
RybelsusSemaglutide28$28,061
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$24,659
XareltoRivaroxaban32$22,428
ProliaDenosumab12$19,681
TrulicityDulaglutide18$19,660
FarxigaDapagliflozin Propanediol19$10,712
NexiumEsomeprazole Magnesium20$10,067
Advair HfaFluticasone Propion/Salmeterol22$8,993
Incruse ElliptaUmeclidinium Bromide24$8,350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$454$131,878120 claims
Lilly USA, LLCMounjaro, Trulicity$91$88,65874 claims
PfizerEliquis$184$76,25984 claims
GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta$574$64,652123 claims
MerckJanuvia$197$28,91130 claims
Johnson & JohnsonXarelto$181$22,42832 claims
AmgenProlia$233$19,68112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Jamestown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →